People have been asking what Oncotarget is, and the answer is quite simple. As the name implies, Oncotarget ‘targets’ oncology — the study and treatment of cancer. Oncotarget is a journal, an online semiweekly journal devoted to the study and treatment of cancer. The journal sometimes publishes articles on other research that might be of value to the medical and oncology fields. Check the journal at SCImago Journal & Country Rank.
Oncology is the study of cancer and its treatment. Since Oncotarget ‘targets’ cancer, it is no surprise that in July of 2017, Oncotarget published an article by a number of Chinese researchers on the subject of thyroid cancer. The research material was made available to doctors and researchers all over the world who were interested in treating thyroid cancer, simply by reading and investigating the material published in Oncotarget. This had a major impact on the medical field, as the treatment described by the researchers in the journal was successfully used and completed by doctors elsewhere. The results proved and solidified the results of using Oncotarget for everyday use and research. Download output styles at Endnote.com
Oncotarget publishes other detailed medical research from a variety of sources, and much of its publication data relates to the cancer research being done by its contributors.
Doctors Mikhail Blagosklonny and Andrei V. Gudkov are the editors in chief of the semiweekly journal. Dr. Blagosklonny received his degree in medicine in Russia. Dr. Gudkov is associated with the Roswell Park Cancer Institute.
Oncotarget has been of great service to researchers, doctors, and patients over the past few years. We look forward to much more from this semiweekly journal of medical research.
Cancer Treatment Centers of America (CTCA) operates in five hospitals in the US. It runs in Atlanta, Phoenix, Chicago, Tulsa, and Philadelphia. CTCA has consistently been rated as one of the best centers in the US that offer high-quality care and patient experience. The center has partnered with other players in the healthcare industry to provide a personalized technical recommendation. The other partners of CTCA are Allscripts and NantHealth. Eviti is a NantHealth clinical decision care solution. The three healthcare providers partnered to form the Clinical Pathways program, which helps to inform on the cancer treatment process without causing disruptions to the clinical workflow of patients.
The Clinical Pathways offers real-time functionality, access to referenced response rates, toxicity, and adverse drug reactions, supporting clinical data, and comparisons between cancer treatment options. Eviti will be integrated with Allscripts Sunrise HER for the platform to enable physicians to retrieve information from an impartial Evidence-Based Medical Library. The library has more than 2,700 of the best evidence-based treatment regimens detailing all types of cancers, all modalities, and cancer subtypes. The library is compiled from oncology associations, clinical informatics experts, oncology nurses, advisory board oncology experts, and peer-reviewed literature. Health providers can present directly into order entry via open technique ability offered by Allscripts after a regimen is selected.
About Cancer Treatment Centers of America
It is a center that specializes in treating cancer patients and disseminating information to their families. CTCA uses in integrative treatment model to treat cancer using conventional methods such as chemotherapy, surgery, and immunotherapy. It also provides patients with evidence-informed supportive rehabilitations to manage side effects of cancer. CTCA operates in five hospitals in the US, which are situated in major metropolitan areas. All the centers have cancer professionals who use advanced treatments and leading-edge technology to offer specialized care.
To Learn More Click Here
One of the greatest challenges in the fight against cancer is the inadequacy of crucial information that is pertinent in developing more effective treatment and management options. However, over the years scientists such as Mikhail Blagosklonny have made great progress in demystifying the scourge that has become one of the leading causes of death globally in a few short years. The professor at Roswell Park Cancer Institute who specializes in oncology is also a research scientist with several scientific publications touching on oncology and aging to his name. With more studies indicating that the manifestation of aging has some commonalities with that of cancer, the First Pavlov State Medical University of St. Petersburg trained oncologist believes that understanding the signaling pathways for aging especially Target of Rapamycin (TOR) has the potential of finding the treatment for more than just aging. It has the potential of treating of cardiovascular diseases, cancer and Parkinson’s disease among others.
Drawing from his years of scholarly experience working as a research scientist, professor across several institutions including New York Medical College, Mikhail Blagosklonny believes that conceptualizing the TOR signaling pathway can create a model that build upon previous studies into its potential. His hypothesis postulates that the popular cancer drug has the anti-aging qualities and hence can be used to extend the human lifespan. This is because it eliminates the hyper-immunity of the body that is responsible for aging of cells. He also holds that TOR-centric model is hinged on inactivation of genes responsible for extending lifespan, increasing cell senescence and eliminating age-related diseases. With lifespan extended, Mikhail Blagosklonny believes that new causes of death will emerge over time.
Scholarly and professional Dedication to Understanding Oncology
Mikhail Blagosklonny has unrivalled grasp of oncology and its related conditions such as aging. He is a renowned scholar in the field with two degrees. He specialized in internal medicine for Doctor of Medicine studies. For his Doctor of Philosophy studies, he specialized in cardiology and experimental medicine. He is strongly convicted that, with time, scientists will find a cure for both cancer and aging. He believes that Rapamycin, which is currently being used for this purpose, holds a greater potential of tackling these conditions. This is most of his researches have focused on cell-related topics including anticancer therapeutic, mitosis, tumor suppressors and signal transduction. His professional career, which has also seen him work as a research scientist at Ordway Research Institute, has also seen him research on apoptosis, mechanisms of aging, cell cycle and ontogenesis. Mikhail Blagosklonny is a reputable authority on the topic of oncology. This is why has dedicated his scholarly and professional life to researching and disseminating information on cancer. Towards this end, he cofounded the open access online medical journal, Oncotarget, which is published weekly in English. He also serves as the coeditor-in-chief for the multiple peer-reviewed journal and several others including Cell Cycle and Aging. Additionally, he lends his vast experience in oncology for several other journals as a member of the editorial board. This includes Cell Death & Differentiation and Cancer Biology & Therapy.
Clay B. Siegall is a Ph.D. holder and a time-proven scientist. His involvement revolves around research, where he focuses on cancer therapies. Clay earned his B.S in Zoology from the University of Maryland and again pursued his Ph.D. from George Washington University. He is committed to finding a lasting solution for the cancer patients and their loved ones. His career life begun taking shape when he worked with National Cancer Institute, National Institutes of Health, between 1988 and 1991. Again in 1991, he started working with the Bristol-Myers Squibb Pharmaceutical Research Institute until 1997. Dr. Siegall appreciates the invaluable skills he gained in those institutions that he served before co-founding Seattle Genetics.
General Information About Seattle Genetics
Siegall co-founded Seattle in 1998, and he serves there as the president, CEO and board chairman. The primary reason for the inception was to enhance cancer therapies. There was a great motivation that came from Clay’s father’s illness. Siegall’s father was diagnosed with cancer when he was 19. He suffered from the life-threatening disease for five years, and Clay was watching. Mr. Clay Siegall got motivated to pursue cancer treatment so as to deliver the patients from the agony. The company has registered great milestones so far. They have succeeded in creating drugs that are FDA approved, the major one being in 2011, where their first ADC products were approved.
Various Administrative Positions Held by Clay Siegall
Mr. Clay served at Onyx Pharmaceuticals, Inc. as the Vice President and Chief Financial Officer. As well, he served as an independent director for Ultragenyx. The pharmaceuticals firm took him in because they believed in his proven proficiency in the biopharmaceutical industry. When joining the company, Clay appreciated the significant progress they had made in their clinical programs. Being a supporter of development, he pledged his allegiance in working with Ultragenyx in achieving greater goals ahead of them.
Clay’s Appointment at Mirna Therapeutics Inc.
In January 2013, Clay experienced a boost in his career when he got appointed to the board of directors at Mirna Therapeutics Inc. The firm mainly focuses on creation and commercialization of microRNA (miRNA) therapeutics. Being an exciting environment for cancer research, it got him serving in his most relevant area of specialty.